Beta Bionics, Inc. (NASDAQ:BBNX) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Twelve analysts give Beta Bionics an average rating of Moderate Buy (1 sell, 3 hold, 7 buy, 1 strong buy) with an average 1‑year price target of $22.00.
• The stock opened at $11.17 and trades well below its 200‑day SMA ($19.79) with a market cap of about $497.7M and high volatility (beta 5.06); the company posted Q1 EPS of ($0.49) beating estimates with $27.63M revenue but still has a ~60% negative net margin and analysts forecast -2.14 EPS for the year.

Shares of Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) have been given an average rating of "Moderate Buy" by the twelve brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $22.00.

A number of equities research analysts have issued reports on BBNX shares. Leerink Partners decreased their price target on shares of Beta Bionics from $25.00 to $24.00 and set an "outperform" rating for the company in a report on Wednesday. Bank of America lowered Beta Bionics from a "buy" rating to a "neutral" rating in a research note on Friday, January 9th. UBS Group upgraded Beta Bionics to a "strong-buy" rating in a research note on Monday, February 9th. Robert W. Baird lowered their target price on Beta Bionics from $28.00 to $14.00 and set a "neutral" rating on the stock in a report on Wednesday, February 18th. Finally, The Goldman Sachs Group dropped their price target on Beta Bionics from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, April 9th.

Beta Bionics Trading Down 2.3%

Shares of Beta Bionics stock opened at $11.17 on Friday. The firm has a fifty day simple moving average of $11.45 and a 200-day simple moving average of $19.79. The stock has a market capitalization of $497.74 million, a price-to-earnings ratio of -7.40 and a beta of 5.06. Beta Bionics has a 1-year low of $8.80 and a 1-year high of $32.71.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. The business had revenue of $27.63 million for the quarter. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. As a group, research analysts predict that Beta Bionics will post -2.14 earnings per share for the current year.

Institutional Investors Weigh In On Beta Bionics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. GPS Wealth Strategies Group LLC increased its position in Beta Bionics by 45.0% during the third quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company's stock worth $29,000 after acquiring an additional 450 shares during the period. Summit Securities Group LLC acquired a new position in Beta Bionics during the 4th quarter valued at $52,000. Caitong International Asset Management Co. Ltd boosted its holdings in Beta Bionics by 1,075.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company's stock valued at $61,000 after purchasing an additional 1,818 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Beta Bionics by 203.6% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company's stock valued at $47,000 after purchasing an additional 1,594 shares during the period. Finally, Strs Ohio acquired a new stake in Beta Bionics in the 1st quarter worth $29,000.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.